目的 研究復(fù)方雪蓮膠囊聯(lián)合塞來昔布膠囊治療強(qiáng)直性脊柱炎的臨床療效。方法 選取2018年6月—2019年6月在鄭州大學(xué)第一附屬醫(yī)院（惠濟(jì)院區(qū)）治療的100例強(qiáng)直性脊柱炎患者為研究對象，將所有患者隨機(jī)分為對照組和治療組，每組各50例。對照組患者口服塞來昔布膠囊，1粒/次，1次/d。治療組在對照組基礎(chǔ)上口服復(fù)方雪蓮膠囊，2粒/次，2次/d。兩組患者持續(xù)治療2個(gè)月。觀察兩組的臨床療效，比較兩組的臨床癥狀緩解時(shí)間、巴氏強(qiáng)直性脊柱炎疾病活動(dòng)指數(shù)（BASDAI）評分和巴氏強(qiáng)直性脊柱炎功能指數(shù)（BASFI）評分、枕墻距、生活質(zhì)量綜合評定問卷（GQOLI-74）評分、血清炎性因子水平。結(jié)果 治療后，對照組和治療組的總有效率分別為78.00%、96.00%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者下腰背疼痛、外周關(guān)節(jié)腫脹、外周關(guān)節(jié)疼痛緩解時(shí)間顯著短于對照組（P<0.05）。治療后，兩組患者BASDAI評分、BASFI評分、枕墻距均顯著降低，生活質(zhì)量綜合評定問卷（GQOLI-74）評分顯著升高（P<0.05），且治療后治療組BASDAI評分、BASFI評分、枕墻距低于對照組，GQOLI-74評分高于對照組（P<0.05）。治療后，兩組血清C反應(yīng)蛋白（CRP）、白細(xì)胞介素-1β（IL-1β）和腫瘤壞死因子-α（TNF-α）水平顯著降低（P<0.05）；并且治療組血清CRP、IL-1β和TNF-α水平降低較明顯（P<0.05）。結(jié)論 復(fù)方雪蓮膠囊聯(lián)合塞來昔布膠囊治療強(qiáng)直性脊柱炎具有較好的臨床療效，能夠改善臨床癥狀，提高患者生活質(zhì)量，降低血清炎性因子水平，值得在臨床上推廣應(yīng)用。

Objective To study the efficacy of Compound Xuelian Capsules combined with Celecoxib Capsules in treatment of ankylosing spondylitis. Methods Patients (100 cases) with ankylosing spondylitis in the First Affiliated Hospital of Zhengzhou University (Huiji Campus) from June 2018 to June 2019 were randomly divided into control and treatment groups, and each group had 50 cases. Patients in the control group were po administered with Celecoxib Capsules, 1 grains/time, once daily. Patients in the treatment group were po administered with Compound Xuelian Capsules on the basis of the control group, 2 grains/time, twice daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacies were evaluated, and clinical symptom remission time, BASDAI score, BASFI score, sleeper wall distance and GQOLI-74 score, and the levels of serum inflammatory factors in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 78.00% and 96.00%, respectively, and there was difference between two groups (P<0.05). After treatment, the remission time of peripheral joint pain, low back pain and peripheral joint swelling in the two groups was significantly shorter than that in the control group (P<0.05). After treatment, BASDAI scores, BASFI scores, and occipital wall distance in the two groups were significantly decreased, but GQOLI-74 scores in two groups were significantly increased (P<0.05). And the BASDAI score, BASFI score and occipital wall distance of the treatment group were lower than those of the control group, but the GQOLI-74 score of the treatment group was higher than that of the control group (P<0.05). After treatment, the serum levels of CRP, IL-1β, and TNF-α in the two groups were significantly decreased (P<0.05). And the serum levels of CRP, IL-1β, and TNF-α in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Compound Xuelian Capsules combined with Celecoxib Capsules has clinical curative effect in treatment of ankylosing spondylitis, can improve the clinical symptoms and the quality of life of patients, reduce the serum level of inflammatory factors, which is worthy of clinical application.

R976

河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃項(xiàng)目（201602019）